26257-93-2

Basic information

• Product Name: Benzoic acid, 2-[(ethylamino)thioxomethyl]hydrazide
• CAS NO: 26257-93-2
• Molecular Formula: C10H13N3OS
• Molecular Weight: 223.299
• Mol File: 26257-93-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-[(ethylamino)thioxomethyl]hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-[(ethylamino)thioxomethyl]hydrazide(26257-93-2)
• EPA Substance Registry System: Benzoic acid, 2-[(ethylamino)thioxomethyl]hydrazide(26257-93-2)

Safety Data

• Hazardous Substances Data: 26257-93-2(Hazardous Substances Data)

Upstream product

• 13431-34-0 N-ethylthiosemicarbazide 
• 98-88-4 benzoyl chloride 
• 93-58-3 benzoic acid methyl ester 
• 93-89-0 benzoic acid ethyl ester 
• 65-85-0 benzoic acid 

Downstream Products

• 26131-61-3 3-mercapto-4-ethyl-5-phenyl-1,2,4-triazole 
• 485334-41-6 2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone 
• 1617-98-7 N-ethyl-5-phenyl-1,3,4-oxadiazole-2-amine 
• 113966-37-3 Anhydro 8-ethyl-5-hydroxy-2-phenyl-7-oxo-1,3,4-oxadiazolo<3,2-a>pyrimidinium hydroxide 
• 113966-44-2 N-Ethyl-N-(5-phenyl-1,3,4-oxadiazol-2-yl)malonamic acid 
• 26131-61-3 4-ethyl-2,4-dihydro-5-phenyl-3H-1,2,4-triazole-3-thione 
• 91265-79-1 2-(ethylamino)-5-phenyl-1,3,4-thiadiazole 

Relevant articles and documents

Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity

New N-4-piperazinyl ciprofloxacin-triazole hybrids 6a-o were prepared and characterized. The in vitro antimycobacterial activity revealed that compound 6a experienced promising antimycobacterial activity against Mycobactrium smegmatis compared with the reference isoniazide (INH). Additionally, compound 6a exhibited broad spectrum antibacterial activity against all the tested strains either Gram-positive or Gram-negative bacteria compared with the reference ciprofloxacin. Also, compounds 6g and 6i displayed considerable antifungal activity compared with the reference ketoconazole. DNA cleavage assay of the highly active compounds 6c and 6h showed a good correlation between the Mycobactrium cleaved DNA gyrase assay and their in vitro antimycobactrial activity. Moreover, molecular modeling studies were done for the designed ciprofloxacin derivatives to predict their binding modes towards Topoisomerase II enzyme (PDB: 5bs8).

Synthesis and invitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold

In recent years, clinical symptoms resulting from West Nile virus (WNV) infection have worsened in severity, with an increased frequency in neuroinvasive diseases among the elderly. As there are presently no successful therapies against WNV for use in humans, continual efforts to develop new chemotherapeutics against this virus are highly desired. The viral NS2B-NS3 protease is a promising target for viral inhibition due to its importance in viral replication and its unique substrate preference. In this study, a WNV NS2B-NS3 protease inhibitor with a 2-{6-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold was identified during screening. Optimization of this initial hit by synthesis and screening of a focused compound library with this scaffold led to the identification of a novel uncompetitive inhibitor (1a24, IC50=3.4±0.2μM) of the WNV NS2B-NS3 protease. Molecular docking of 1a24 into the WNV protease showed that the compound interferes with productive interactions of the NS2B cofactor with the NS3 protease and is an allosteric inhibitor of the WNV NS3 protease.

Mesoionic isoxazolo[2,3-a]pyrimidinediones and 1,3,4-oxadiazolo[3,2-a]pyrimidinediones as potential adenosine antagonists

-